FDA Approves First Oral Hormone Therapy For Treating Advanced Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix) for the treatment of adults with advanced prostate cancer. Orgovyx is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thereby reducing the amount of testosterone the testicles are able to make. The FDA granted approval of Orgovyx to Myovant Sciences.

The safety and efficacy of Orgovyx was evaluated in a randomized, open-label trial in men with advanced prostate cancer. The individuals randomly received either Orgovyx once daily or injections of leuprolide, another hormone-targeting . . .